192 related articles for article (PubMed ID: 25663076)
21. Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.
Mao Y; Triantafillou G; Hertlein E; Towns W; Stefanovski M; Mo X; Jarjoura D; Phelps M; Marcucci G; Lee LJ; Goldenberg DM; Lee RJ; Byrd JC; Muthusamy N
Clin Cancer Res; 2013 Jan; 19(2):347-56. PubMed ID: 23209030
[TBL] [Abstract][Full Text] [Related]
22. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer.
Jenkins DE; Yu SF; Hornig YS; Purchio T; Contag PR
Clin Exp Metastasis; 2003; 20(8):745-56. PubMed ID: 14713108
[TBL] [Abstract][Full Text] [Related]
23. Liposomal gemcitabine (GemLip)-efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts.
Jantscheff P; Esser N; Graeser R; Ziroli V; Kluth J; Unger C; Massing U
Prostate; 2009 Aug; 69(11):1151-63. PubMed ID: 19399788
[TBL] [Abstract][Full Text] [Related]
24. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model.
Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM
Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas9 genome and long non-coding RNAs as a novel diagnostic index for prostate cancer therapy via liposomal-coated compounds.
Kadry MO; Abdel-Megeed RM
PLoS One; 2024; 19(5):e0302264. PubMed ID: 38723038
[TBL] [Abstract][Full Text] [Related]
26. Parathyroid hormone-related protein and bone metastases.
Guise TA
Cancer; 1997 Oct; 80(8 Suppl):1572-80. PubMed ID: 9362424
[TBL] [Abstract][Full Text] [Related]
27. Angiotensin-(1-7) attenuates metastatic prostate cancer and reduces osteoclastogenesis.
Krishnan B; Smith TL; Dubey P; Zapadka ME; Torti FM; Willingham MC; Tallant EA; Gallagher PE
Prostate; 2013 Jan; 73(1):71-82. PubMed ID: 22644942
[TBL] [Abstract][Full Text] [Related]
28. Cediranib inhibits both the intraosseous growth of PDGF D-positive prostate cancer cells and the associated bone reaction.
Najy AJ; Jung YS; Won JJ; Conley-LaComb MK; Saliganan A; Kim CJ; Heath E; Cher ML; Bonfil RD; Kim HR
Prostate; 2012 Sep; 72(12):1328-38. PubMed ID: 22213159
[TBL] [Abstract][Full Text] [Related]
29. Development of a bone-targeted pH-sensitive liposomal formulation containing doxorubicin: physicochemical characterization, cytotoxicity, and biodistribution evaluation in a mouse model of bone metastasis.
Ferreira Ddos S; Faria SD; Lopes SC; Teixeira CS; Malachias A; Magalhães-Paniago R; de Souza Filho JD; Oliveira BL; Guimarães AR; Caravan P; Ferreira LA; Alves RJ; Oliveira MC
Int J Nanomedicine; 2016; 11():3737-51. PubMed ID: 27563241
[TBL] [Abstract][Full Text] [Related]
30. Co-delivery of everolimus and vinorelbine via a tumor-targeted liposomal formulation inhibits tumor growth and metastasis in RCC.
Pal K; Madamsetty VS; Dutta SK; Mukhopadhyay D
Int J Nanomedicine; 2019; 14():5109-5123. PubMed ID: 31371950
[TBL] [Abstract][Full Text] [Related]
31. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
32. LyP-1-conjugated PEGylated liposomes: a carrier system for targeted therapy of lymphatic metastatic tumor.
Yan Z; Wang F; Wen Z; Zhan C; Feng L; Liu Y; Wei X; Xie C; Lu W
J Control Release; 2012 Jan; 157(1):118-25. PubMed ID: 21827801
[TBL] [Abstract][Full Text] [Related]
33. PCSD1, a new patient-derived model of bone metastatic prostate cancer, is castrate-resistant in the bone-niche.
Godebu E; Muldong M; Strasner A; Wu CN; Park SC; Woo JR; Ma W; Liss MA; Hirata T; Raheem O; Cacalano NA; Kulidjian AA; Jamieson CA
J Transl Med; 2014 Oct; 12():275. PubMed ID: 25278011
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of bone loss with surface-modulated, drug-loaded nanoparticles in an intraosseous model of prostate cancer.
Adjei IM; Sharma B; Peetla C; Labhasetwar V
J Control Release; 2016 Jun; 232():83-92. PubMed ID: 27090164
[TBL] [Abstract][Full Text] [Related]
35. Liposomal Irinotecan Accumulates in Metastatic Lesions, Crosses the Blood-Tumor Barrier (BTB), and Prolongs Survival in an Experimental Model of Brain Metastases of Triple Negative Breast Cancer.
Mohammad AS; Griffith JI; Adkins CE; Shah N; Sechrest E; Dolan EL; Terrell-Hall TB; Hendriks BS; Lee H; Lockman PR
Pharm Res; 2018 Jan; 35(2):31. PubMed ID: 29368289
[TBL] [Abstract][Full Text] [Related]
36. Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis.
Anderson R; Franch A; Castell M; Perez-Cano FJ; Bräuer R; Pohlers D; Gajda M; Siskos AP; Katsila T; Tamvakopoulos C; Rauchhaus U; Panzner S; Kinne RW
Arthritis Res Ther; 2010; 12(4):R147. PubMed ID: 20642832
[TBL] [Abstract][Full Text] [Related]
37. Liposomes for the treatment of prostate cancer therapy: A review.
Sahoo CK; Sahoo NK; Sahu M; Gupta J
Cancer Treat Res Commun; 2024; 39():100792. PubMed ID: 38367412
[TBL] [Abstract][Full Text] [Related]
38. Ultrasound enhanced antitumor activity of liposomal doxorubicin in mice.
Hagtvet E; Evjen TJ; Olsen DR; Fossheim SL; Nilssen EA
J Drug Target; 2011 Sep; 19(8):701-8. PubMed ID: 21524240
[TBL] [Abstract][Full Text] [Related]
39. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
40. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
